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Abstract
Transthyretin amyloidosis is a conformational pathology characterized by the extracellular
formation of amyloid deposits and the progressive impairment of the peripheral nervous
system. Point mutations in this tetrameric plasma protein decrease its stability and are
linked to disease onset and progression. Since non-mutated transthyretin also forms amy-
loid in systemic senile amyloidosis and some mutation bearers are asymptomatic through-
out their lives, non-genetic factors must also be involved in transthyretin amyloidosis. We
discovered, using a differential proteomics approach, that extracellular chaperones such as
fibrinogen, clusterin, haptoglobin, alpha-1-anti-trypsin and 2-macroglobulin are overrepre-
sented in transthyretin amyloidosis. Our data shows that a complex network of extracellular
chaperones are over represented in human plasma and we speculate that they act syner-
gistically to cope with amyloid prone proteins. Proteostasis may thus be as important as
point mutations in transthyretin amyloidosis.
Introduction
Transthyretin amyloidosis (ATTR) is an autosomal dominant degenerative disease character-
ized by the formation of amyloid fibril deposits, mainly composed of transthyretin (TTR), in
different organs and tissues [1, 2]. These amyloid deposits hinder organ function, lead to their
failure and, ultimately, death. ATTR has been associated, mainly by in vitro studies [3], with
single amino acid substitutions in TTR, a plasma protein responsible for the transport of thy-
roxine and retinol in the blood, the latter via the association with the retinol-binding protein
[4].
The only effective therapeutic option for ATTR is liver transplantation from cadaveric
donors since plasma TTR is produced mainly in the liver. Moreover, domino liver transplant
from ATTR patients, a practice recently introduced to obviate the shortage of livers available
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for transplantation, introduces TTR mutated forms in circulation, increasing the risk of ATTR
development [5].
The main hypothesis for ATTR pathogenesis considers the tetramer instability favoring the
dissociation to non-native monomeric species with the ability to self-associate. These soluble
aggregates evolve to insoluble aggregates and amyloid fibers with the characteristic β-cross
sheet structure found in several neurodegenerative disorders such as Alzheimer’s and Parkin-
son’s diseases [6].
This model, however, fails to explain two crucial aspects of amyloid formation. First, non-
mutated TTR also forms amyloid, causing systemic senile amyloidosis [7]. Mutations only
accelerate the intrinsic amyloidotic behavior of this protein. Second, time to disease onset var-
ies by decades for different patients bearing the same mutation, and individuals transplanted
with liver from transthyretin amyloidotic individuals present an amyloidotic behavior much
faster that individual bearing amyloidogenic mutations [8]. Discordant disease progression in
homozygote twins From Sweden and Spain was reported. In a case, one of the twins underwent
liver transplantation, whereas the other is completely healthy, showing no symptoms 8 years
after the onset of his brother disease [9, 10, 11]. It is also important to note that, homozygous
ATTR V30M patients appear not to develop a more aggressive disease than heterozygous ones
[12]. Genetic factors alone do not explain all the process for amyloid formation and other fac-
tors should be taken in consideration. These questions point to the involvement of multiple
factors in ATTR development. Moreover, several studies described structural transient states
[13,14,15] during fibrillation that under the correct circumstances, do not further convert into
amyloid fibrils [16,17].
Proteome analysis in different biological samples is being increasingly used for clinical diag-
nosis and identification of protein biomarkers for the disease onset of various pathologies.
2-DE is still a promising research area for markers discovery [18]: the most important advan-
tage of plasma proteomics is the prospect of a noninvasive and easy sampling system of diagno-
sis, which might reduce the need of any kind of biopsy. The practical utility of 2-DE for studies
of the high abundance plasma proteome has been substantial. Because the first dimension of
the procedure (isoelectric focusing) is exquisitely sensitive to molecular charge and the second
dimension (SDS electrophoresis) is sensitive to polypeptide length, 2-DE is very effective at
revealing genetic variants (about one-third of which differ in net charge from wild type (WT),
proteolytic cleavages, and variations in sialic acid content [19].
In this work we evaluated the plasma proteome of ATTR individuals in relation to control
individuals. We observed that several proteins were differentially expressed, namely extracellu-
lar chaperones, in agreement to what was previously observed in other amyloid diseases. More-
over we also observed increased proteolytic activity in ATTR plasma.
Methods
Plasma Collection
Blood samples from control individuals, ATTR patients (three females each, age range 26–33
years) and patients subjected to liver transplantation, both domino liver transplantation (DLT)
and cadaveric donor liver transplantation (OLT) (four females each, age range 32–41 years)
were collected by venous puncture to citrate containing tubes centrifuged at 1,800 g for 5 min
at 4°C and the collected plasma was immediately frozen at -80°C until further analysis. All
patients gave informed written consent and the protocol was approved according to EEC ethic
rules and the Helsinki protocol. This study was approved by the Ethics committee of the Curry
de Cabral Hospital.
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Polyacrylamide Gel Electrophoresis. Plasma proteins were separated by SDS-PAGE
(12%), in mini-gel format (7x7 cm Tetra system from Bio-Rad). Twenty micrograms of plasma
protein were loaded per lane. Protein concentration was determined by the Bradford protein
assay, using bovine serum albumin (BSA) as a standard (Bio-Rad). Samples were diluted 10
fold in MilliQ water and mixed with reduction buffer (62.5 mM Tris-HCl, pH 6.8, 20% (v/v)
Glycerol, 2% (w/v) SDS, 5% (v/v) -mercaptoetanol). Prior to electrophoresis, samples were
heated at 100°C for 5 min. Protein bands were stained with Coomassie brilliant blue R-250.
Two Dimensional Electrophoresis
Samples containing 350 μg of plasma protein were used for IEF (isoelectric focusing) using
immobiline dry strips of 13 cm, respectively, with a non linear pH gradient from 3 to 11 [20,
21] (Amersham Biosciences). After IEF separation, proteins were reduced and alkylated in the
dry strip. Second dimension SDS-PAGE was performed using 12% acrylamide/bysacrylamide,
following general procedures. Protein spots were stained with Coomassie brilliant blue R-250.
Image analysis
Gels images were acquired using the IMAGE SCANER (Amersham Biosciences) and the 2-DE
gel images were exported to the Samespots Analysis software program (Nonlinear Dynamics).
This software compares computer images of 2-DE gels to determine differential protein expres-
sion and accurately identifies increased or decreased proteins on the basis of spots staining
intensity. When spots were detected, the original gel image was normalized by a filtration pro-
cedure and then the 3-D Gaussian spots were created. After spot detection in gels, a match set
was generated and a standard gel image as a master map, made by merging the Gaussian
images of each ATTR patients. This set was matched to the protein spots from healthy subjects
primary gels. The protein spots in a comparison set of gels were quantitatively, qualitatively,
and statistically analyzed.
Western Blotting
For western blot analysis, proteins were transferred from the gel to PVDF membranes (Milli-
pore) and stained with Ponceau S to monitor protein transfer. Membranes were blocked over-
night at 4°C with TBS (10 mM Tris–HCl, 150 mMNaCl, pH 7.5) containing 5% skimmed
milk. Afterwards, the membranes were incubated overnight at 4°C with the primary antibody
used in TBS-T (TBS Buffer with 0.1% Tween 20) containing 1% skimmed milk. Antibodies
used were: anti human TTR polyclonal antibody (DAKO) at a dilution of 1:5000, anti-fibrino-
gen (Calbiochem) at a dilution of 1:10000, e C-reactive protein (Santa Cruz Biotechnology) at a
dilution of 1:500, Vitamin D-binding protein (DBP) (Santa Cruz Biotechnology) at a dilution
of 1:500, Alpha-2-Macroglobulin (Santa Cruz Biotechnology) at a dilution of 1:500 and 1 anti-
trypsin (Santa Cruz Biotechnology) at a dilution of 1:500.
Membranes were washed three times for 10 min each with TBS-T and incubated for 1 h at
room temperature with anti-rabbit IgG (Roche) (at 1:10000 dilution) and anti-mouse IgG
(Roche) (at 1:10000 dilution), for TTR and fibrinogen. Immunoreactivity was detected with
Pierce ecl western blotting substrate, following the manufacturer’s instructions (Pierce). Each
dried blot was scanned at 600 dpi (dots per inch) and saved as a TIFF file. Image analysis was
performed using the public domain ImageJ program (National Institutes of Health, and avail-
able at http://rsb.info.nih.gov/ij/), using the “Gel Analysis” functions. Background correction
was done using a “rolling ball”method with a radius of 4 times the width of a band. The result
of the analysis is a value for each band which is proportional to the Integrated Density Value
(IDV) of that band.
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In Gel Protein Digestion
Protein bands were manually excised from the gels and digested using trypsin as described [22,
23]. Briefly, gel protein bands were washed in milliQ water, distained in 50% acetonitrile (ACN
and subsequently with 100% ACN. Cys residues were reduced with 10 mM DTT and alkylated
with 50 mM iodoacetamide. Gel pieces were dried by centrifugation under vacuum and rehy-
drated in digestion buffer containing 50 mMNH4HCO3 and 6.7 ng/µL of trypsin (modified
porcine trypsin, proteomics grade, Promega) at 4°C. After 30 min the supernatant was
removed and discarded and 20 µL of 50 mM NH4HCO3 were added. Digestions were allowed
to proceed at 37°C overnight (16–18 hours). After digestion, the remaining supernatant was
removed and stored at -20°C.
Mass Spectrometry
To identify target proteins, a MALDI-TOF/TOF 4800 plus mass spectrometer (Applied Biosys-
tems, Foster City, CA, USA) was used, as previously described [24]. Desalting and concentra-
tion of tryptic peptides was carried out with home-made chromatographic microcolumns
using GELoader tips packed with POROS R2 (Applied Biosystems, Foster City, CA, USA). The
peptides were directly eluted from the micro columns onto the MALDI plate using α-ciano-
4-hydroxycinnamic acid (5 mg.ml-1) in 50% (v/v) CH3CN with 0.1% (v/v) formic acid.
MS experiments were performed in positive reflectron mode for monoisotopic peptide mass
determination. The mass spectrometer was externally calibrated using a mixture of des-Arg-
Bradykinin (904.468 Da), angiotensin 1 (1296.685 Da), Glu-Fibrinopeptide B (1570.677 Da),
ACTH (1–17) (2093.087 Da), and ACTH (18–39) (2465.199) (4700 Calibration Mix, Applied
Biosystems, Foster City, CA, USA). MS spectra was collected in a result-independent acquisi-
tion mode, typically using 1000 laser shots per spectra and a fixed laser intensity of 3000 V. For
tandem experiments, fifteen of the strongest precursors were selected for MS/MS, the weakest
precursors being fragmented first. MS/MS analyses were performed using CID (Collision
Induced Dissociation) with 1 kV collision energy and 1 x 106 torr air pressure. 2000 laser shots
were collected for each MS/MS spectrum using a fixed laser intensity of 4000V. Raw data were
generated by the 4000 Series Explorer Software v3.0 RC1 (Applied Biosystems, Foster City, CA,
USA) and tryptic peptide contaminantm/z peaks resulting from trypsin autodigestion
(842.508 Da; 1045.564 Da; 2211.108 Da; 2225.119 Da) were excluded when generating the pep-
tide mass list used for comparison with the theoretical tryptic digest. Proteins were identified
by the GPS explorer (Applied Biosystem) and further confirmed using the ProteinPilot soft-
ware (Applied Biosystem).
TTR quantification was performed as described [25, 26], briefly samples were desalted and
concentrated using reverse phase
Poros R2 (Applied Biosystems) and eluted directly to the MALDI target AnchorChip (Bru-
kerDaltonics, Bremen, Germany) with the appropriated matrix, according to the manufacturer
procedure. Matrix solution of α-cyano-4-hydroxycinnamic acid (CHCA; Fluka) was prepared
at a concentration of 10 μg/μL in 50% ACN with 0.1% TFA. Peptide mixtures were analyzed by
MALDI-FTICR-MS in a Bruker Apex Ultra, Apollo II combi-source (Bruker Daltonics, Bre-
men, Germany), with a 7 Tesla magnet (Magnex corporation, Oxford UK). Monoisotopic pep-
tide masses were determined using the SNAP 2 algorithm in Data Analysis software version 3.4
(BrukerDaltonics). External calibration was performed by using the BSA tryptic digest spec-
trum, processed and analyzed with Biotools 3.1 (BrukerDaltonics, Bremen, Germany).
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Proteolytic activity
In order to evaluate the proteolytic content in human plasma from healthy subjects and ATTR
patients, a Pierce Fluorescent Protease Assay Kit was used, according to the manufacturer’s
instructions. Briefly, the fluorescence measures were carried out with a Fluorolog-3 (Horiba
Jobin Yvon) in a quartz cuvette with 0.5 cm optical path, with standard fluorescein excitation/
emission filters (485/538 nm) and for the calibration trypsin was the general protease chose.
Human plasma samples were diluted 100 x times in TBS (25 mM Tris, 0.15 M NaCl, pH 7.2),
trypsin standards and casein solution were also prepared in this buffer. All samples and stan-
dards were incubated with the substrate at room temperature for 20 min. The estimate of pro-
tease concentration in the sample was calculated by a linear regression with the trypsin
standards and then divided by the total protein amount used on the assay (µg protease/µg pro-
tein). To evaluate a putative cryptic activity of TTR we incubated plasma samples with poly-
clonal antibody anti-TTR. Considering a maximum TTR concentration in plasma of 0.45 g/L
[27], samples were incubated with the same molar ratio of anti-TTR antibody for 1- 2h at
room temperature with stirring at 300 rpm. Protein concentration was determined by the
Bradford protein assay, using BSA as standard (Bio-Rad).
Results
Clinical and Biochemical data
All subjects are heterozygous carriers for the V30M mutation except the controls and DLT
individuals that do not bear any known TTR mutation. ATTR individuals at the time of sample
collection and ATTR transplanted individual at the time of transplantation showed peripheral
polyneuropathy or autonomic polyneuropathy without signs of amyloid deposition [28].
All studied TTR mutation carriers or sequential liver transplanted patients were heterozy-
gous. To validate samples for the future work the differential TTR forms in the plasma were
characterized and relatively quantified as previously described (S1 Fig) [25, 26].
We separated plasma proteins by SDS-PAGE and excised TTR protein band. In the control
and OLT MALDI-FTICR mass spectra, two peptides sequences of WT TTR were found, one
withm/z 1366.759 corresponding to the sequence GSPAINVAVHVFR and a peptide withm/z
1494.853 corresponding to the sequence with a trypsin miss cleavage. The MALDI-FTICR
mass spectra of the TTR tryptic map obtained for the ATTR and DLT samples patients with
a V30M substitution presents an additional peptide, not observed in the control and OLT
mass spectra at m/z 1398.732, corresponding to the 32.056 Da mass shift resulting from the
V30M substitution. Hence, this peptide corresponds to the mutant peptide with the sequence
GSPAINVAMHVFR, characteristic of the TTRV30M variant. The presence of a methionine
residue in this peptide sequence is further confirmed by the observation of a peak with a 17.002
Da mass increment from the mutant peptide (m/z 1414.726, which corresponds to the oxida-
tion of the methionine thioester. We also observed a third peptide (m/z 1526.826) related to
the same sequence, but with a trypsin miss cleavage (GSPAINVAMHVFRK). The peptide
characteristic of WT TTR (1366.759 sequence GSPAINVAVHVFR) is clearly observed in the
sample of ATTR and DLT individuals, as well as the peptide characteristic of V30M TTR vari-
ant (S1 Fig) (S1 Table). This confirmed at the proteome level that all subjects are heterozygous
carriers for the V30Mmutation except the controls and OLT individuals that do not bear any
known TTR mutation. As previously described [29], we performed a relative quantification of
both TTR forms in circulation by using the relative intensity of the peak with m/z of 1366.7556
(WT TTR) to a TTR peptide present in all mass spectra acquired (such as the peak of
1394.6178 m/z).
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2-DE plasma proteomic profile of ATTR patients
Plasma proteins from controls and ATTR were separated by 2-D PAGE and analyzed with the
SameSpots image analysis software. Fig 1A represents a standard gel image obtained by the use
of the SameSpots analysis software, combining the Gaussian images of each gel. This latter was
used as a reference master map for comparison of each 2-DE gel image from ATTR and con-
trols, in the search of differentially expressed plasma proteins. The protein spot patterns were
reproducible among individuals within a study group. Principal component analysis (PCA)
revealed that control individuals show a marked difference from ATTR patients. We observed
clusters of 3 replicates in each group, each cluster corresponding to one individual, with the
three assays corresponding to the three experimental replicates performed (Fig 1B). Similarity
between 2-D PAGE gels was very high, since 95% of spots were detected in 80% of gels from
individual samples. An ANOVA analysis with a cutoff at 1.5 (p< 0.05) revealed 42 differen-
tially expressed spots (Table 1) between ATTR and control individuals, as shown in Fig 1C.
Table 1 contains informations of the identified proteins, including their accession number,
matched peptides as well as theoretical and experimental molecular weight.
We observed that the protein spot presenting the higher variation between the two groups
(3.6 fold–spot 4596) was WT TTR, in agreement with our previous observation that wild type
TTR corresponds to around 60% of the pool of circulating TTR in ATTR individuals [21].
Both TTR variants were identified in spot 4597 in ATTR individuals, and only WT TTR was
identified in this spot in control individuals, however this spot volume did not change between
the two groups. Moreover, TTR presents a higher heterogeneity in ATTR patients since several
PTMs were described for mutant, [30, 31].
Western blot analysis, from SDS-PAGE and 2DE that revealed that TTR bands in 1D elec-
trophoresis and spots in 2D electrophoresis are more heterogeneous in ATTR individuals (Fig
1D and 1E).
The presence of N-glycosylated forms of TTR, as described in the literature, can certainly
contribute for the heterogeneity in the 2DE, since the proteins glycoforms are usually present
as 'trains' of spots in the first dimension, differing also in their molecular weight [32].
Several proteins, previously described as extracellular chaperones overrepresented in ATTR
plasma. In recent years, a substantial body of evidence leads to the suggestion that certain
acute-phase components including fibrinogen [33], alpha 2 macroglobulin (AAG) [34] and
haptoglobin [35] possess chaperone action being able to inhibit in a dose-dependent manner
stress-induced aggregation of a number of unrelated target proteins. Clusterin, an ubiquitous
extracellular mammalian—but not an acute phase protein—also displays a well-characterized
chaperone function [36]. It was also described that alpha 1 anti-trypsin (AAT), which we also
observed overrepresented, might exhibit chaperone like activity, preventing aggregation of Aβ
peptides and related amyloidogenic proteins [37].
The vitamin D binding protein was overrepresented in the plasma of ATTR individuals and
that alpha-trypsin inhibitor heavy chain was under expressed. The similar result was recently
obtained for the differential proteome of serum of Alzheimer individuals [38].
We previously observed that fibrinogen expression is increased in ATTR patients [39] and
this result was confirmed in this work, in which several spots of fibrinogen were over expressed
in ATTR patients. Since most TTR is produced by the liver, the progression of the disease can
be halted by OLT, which leads to the disappearance of the V30M TTR form of the transplant
recipient [40]. To obviate the shortage of livers available for transplantation, DLT was intro-
duced in which a liver from a ATTR patient is transplanted to a patient with liver failure. DLT
introduces mutated TTR variants in circulation, increasing the risk of ATTR development. To
evaluate if DLT individuals presented the same increased levels of the proteins observed in
Tranthyretin Amyloidosis Plasma Proteome
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Fig 1. Proteome analysis of plasma from ATTR individuals. A– 2D-PAGE analysis of plasma proteins. Labeled spots showa statistically significant
variation (p<0.05) and a minimal fold variation of 1.5. These spots were excised, tryptic digested and proteins identified by MS/MS analysis. Average
normalized volumes and protein identifications are presented in Table 1. B–Principle component analysis (PCA) of the 2D results. Each data point in the PCA
represents the global expression values for all spots with a significant ANOVA value (p<0.05). A separation between the control and the ATTR individuals is
clearly observed. C- 2D image analysis of four protein spots and normalized volumes, shown as examples. D-Over expression of western blot analysis of
plasma from four control and four FAP individuals to detect TTR. E—Western blot analysis of a 2DE of serum from four control and four FAP individuals to
detect TTR with super imposition of spots identified as TTR in 2DE.
doi:10.1371/journal.pone.0125392.g001
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Fig 2. Extracellular Chaperones are overrepresented in DLT individuals—SDS-PAGE analysis of
plasma proteins from four individuals after orthotic liver transplantation (OLT) and four individuals
after domino transplantation (DLT) andWestern blot to detect TTR, Fibrinogen, Alpha 1 anti-trypsin
(ITI), Vitamin D binding protein (VBP), alpha 2 microglobolin and C-reactive protein (CRP).Molecular
weight markers are represented on the left hand of the figure and included in the western blots as blue
markers.
doi:10.1371/journal.pone.0125392.g002
Tranthyretin Amyloidosis Plasma Proteome
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Fig 3. Plasma from ATTR individuals presents a higher proteolytic activity. A- Proteolytic activity of
control and ATTR plasmameasured by fluorescent protease assay kit. B–Sequence coverage obtained for
three spots identified as albumin with decreased molecular weight.
doi:10.1371/journal.pone.0125392.g003
Tranthyretin Amyloidosis Plasma Proteome
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ATTR individuals we collected samples of individuals that were subjected to OLT and DLT
and monitored expression of fibrinogen, Vitamin D binding protein, Alpha 2 macroglobolin
and alpha 1 anti-trypsin by western blot analysis. As shown in Fig 2, these proteins are also
found to be overrepresented in DLT individuals, but not in OLT individuals. TTR and the C-
reactive protein, a prototypic acute phase protein, levels do not present any significative differ-
ence between DLT and OLT individuals.
Altogether our observations strength the hypothesis that extracellular chaperones are over-
represented to cope with misfolded protein clearance, as previously suggested in Alzheimer dis-
ease [41] and ATTR [39].
ATTR individuals present higher plasma proteolytic activity
A striking observation in 2DE of plasma from ATTR relatively to controls is the presence of a
large set of proteins with a lower apparent molecular weight than it’s predicted value, which
could indicate the presence of proteolytic fragments. For the majority of these cases we
observed a decrease in sequence coverage for proteins identified by mass spectrometry and
these proteins were identified at a lower molecular weight than the theoretical one (Fig 3B).
We can observe the same protein in several spots with decreasing molecular mass. Take for
example serum albumin which was detected in the spots 2205, 3177 and 4796 with approxi-
mate molecular weight of 70 kDa, 40 kDa and 15 kDa, respectively. Also fibrinogen alpha
chain was detected in several spots of decreasing mass (spots 2391, 2653 and 4461 with respec-
tive molecular masses of 70, 50 and 15 kDa). These observations made us question about a
higher proteolytic activity in the plasma of ATTR individuals. We tested this hypothesis by
measuring the proteolysis of casein in our plasma samples and, as shown in Fig 2C, we
observed a significant increase in the proteolytic activity in the plasma of ATTR patients with a
p-value for the t-test of 9.2583E-12.
TTR has also been established as a cryptic protease, and since one of the proteins found dif-
ferentially represented in the plasma of ATTR patients was APO-AI known to be its substrate
[42] we evaluated the possibility of this increase in the proteolytic activity in ATTR plasma due
to a differential TTR cryptic protease activity. We measured the proteolytic activity in the
plasma in the presence of anti TTR polyclonal antibody. No differences were observed in the
proteolytic content in the plasma of both control and ATTR individuals (data not shown). Pro-
teasomes have also been detected in normal human blood plasma and designated circulating
proteasomes; these have a comparatively low specific activity, a distinct pattern of subtypes and
their exact origin is still enigmatic [43].
Incubation of plasma with MG132, to evaluate if the proteolysis observed was due to a
higher activity of the circulating proteasome, also presented no differences in the proteolytic
content in the plasma of both control and ATTR individuals (data not shown).
Discussion
The major problem associated with the 2-DE analysis of plasma is the presence of abundant
proteins, such as albumin and the wide dynamic range in abundance of other proteins as well
as the tremendous heterogeneity of its predominant glycoproteins. Abundant proteins in the
sample may interfere with the detection of less abundant proteins of interest and for this reason
preclearance methods to deplete the most abundant plasma proteins have become widespread
[44]. However, it has been reported that albumin removal is associated also with the removal of
some other proteins that might be important as well [45]. For this reason, in this work, we
chose not to remove any protein prior to 2-DE analysis. In our case we evaluate the plasma
proteome of ATTR patients relatively to healthy individuals. ATTR patients used in this study
Tranthyretin Amyloidosis Plasma Proteome
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are all heterozygous for TTR mutation (V30M). We previously reported that ATTR individu-
al’s present around 40% less WT TTR relatively to control individuals [26, 29]. In fact we
observed the spot that presents the higher variation between the two groups (3.6 fold) was
identified as TTR, validating the experiment.
Several extracellular chaperones, as clusterin, haptoglobin and alpha2M were found to be
overrepresented. All these extracellular chaperones have the ability to bind misfolded proteins
and thereby inhibit inappropriate protein-protein interactions, preventing aggregation and
maintaining proteins in solution. They demonstrate the ability to influence amyloid formation
in vitro [46,47] and are found colocalized with clinical amyloid deposits in vivo. The amyloid
condition associated to ATTR results from the accumulation of a protein prone to form amy-
loid fibers, and so chaperones and other elements of proteostasis may be overwhelmed by the
larger amount of non native protein present in the extracellular space. We may speculate that
these chaperones are overrepresented in ATTR plasma to overcome the larger amount of a pro-
tein prone to form amyloid fibers, and act collectively. Some of these chaperones were found
overrepresented in several other amyloid diseases, as clusterin in Alzheimer [48, 49]. This
hypothesis is supported by the overexpression of Vitamin D Binding Protein and the under
expression of IHRP as was found in the plasma of Alzheimer´s patients. Altogether these data
point to sticking similarities between amyloid diseases.
Similarly to the extracellular molecular chaperone HP, AMG and clusterin, AAT and other
serpin proteins have also been found to be associated with pathological protein deposits in vari-
ous diseases [50–52]. It has been proposed that such deposits represent the failed attempts of
molecular chaperones to maintain the solubility of misfolded proteins and peptides under dis-
ease specific conditions of high molar substrate excess [46, 53]. Previous reports have indicated
that AAT can inhibit the formation of amyloid fibrils [54]. AAG and AAT has also been identi-
fied as the aggregation inhibitor of the amyloidogenic human alpha-atrial natriuretic peptide
[55]. In another study, albumin, AAT, and immunoglobulins at physiological plasma concen-
trations showed to be potent inhibitors of amyloid beta-peptide (Ab) polymerization [56].
Curiously, we also observed albumin and several Iggs differentially expressed and these extra-
cellular chaperones have been described as overrepresented in several conformational diseases
[57]. It was suggested that this overexpression counteracted the presence of a protein prone to
form amyloid diseases.
DLT using grafts from ATTR patients was first performed in 1995 [58] and more than 400
domino transplant procedures had been carried out by the end of 2005, according to the Famil-
ial Amyloidotic Polyneuropathy World Transplant Registry. The age of onset in ATTR Portu-
guese patients, where TTR shows a substitution of methionine by valine at position 30, ranges
from the late 20s to early 40s. It was, therefore, expected that liver grafts explanted from ATTR
patients would function in recipients without formation of amyloid fibrils for a long period.
However, several recent reports [59, 60] indicate that amyloid deposition or ATTR symptoms
appear in domino recipients much sooner than in ATTR individuals. Our observation that
some extracellular chaperones are overrepresented in individuals that were transplanted with a
sequential liver, starting from that point on to produce mutated TTR makes it highly plausible
that the increased levels of these chaperones is a response to additional request of extracellular
chaperone activities under these pathological conditions [39]. Human fibrinogen specifically
interacts with and suppresses aggregation of a wide spectrum of stressed proteins [61]. It was
proposed that human fibrinogen can interact with prefibrillar species during the fibril forma-
tion process, redirecting the aggregation process. It is also interesting to note that high levels of
human fibrinogen are also related to both Alzheimer’s disease, vascular dementia [62] and
ATTR [39]. The same can be speculated to all the others extracellular chaperones observed to
be overrepresented, as clusterin, that was previously implicated in fibrillogenesis and
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extracellular misfolded protein clearance in Alzheimer disease [63] and its overexpression was
described to have possible protective role in transthyretin deposition in ATTR [57], although
significantly lower levels of circulating clusterin were associated with amyloid deposition in the
heart in ATTR, is what appears to reflect a unique difference in amyloidosis pathology, depen-
dent on organ involvement [64]. In SSA, amyloid fibers present a high percentage of ATTR
fragments starting at position 46, 49 and 52, with the presence of a widely variable proportion
of full length TTR [65]. There is still some controversy in knowing if the proteolytic cleavage
occurs before or after the fibers formation, but according to our results is seems likely that it
occurs already in the bloodstream, before fiber formation [66].
We believe that the overexpression of extracellular chaperone is a hallmark of conforma-
tional diseases and that in the future the most effective therapies for these diseases will be based
on preventive approaches rather than downstream solutions. Moreover these common features
hold great potential to be used as biomarkers for amyloid diseases.
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